Lv31
238 积分 2026-04-28 加入
The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials
7小时前
已完结
Evidence-based approach to management of hepatic encephalopathy in adults
27天前
已完结
Ammonia in liver diseases: A glimpse into the controversies and consensus
27天前
已完结
Time course of regorafenib-associated adverse events in the phase III CORRECT study
1个月前
已关闭
PD-012 Analysis of patients ≥75 years in the open-label phase 3b CONSIGN trial of regorafenib in previously treated metastatic colorectal cancer (mCRC)
1个月前
已完结
Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial
1个月前
已完结
Inter‐Ethnic Differences in the Efficacy and Safety of Tyrosine Kinase Inhibitors Used in Oncology: Insights From Phase 3 Clinical Trials
1个月前
已关闭
Exploring the top 30 drugs associated with drug-induced thrombotic microangiopathy based on the FDA adverse event reporting system
1个月前
已完结
Hyperammonemic encephalopathy after tyrosine kinase inhibitors: A literature review and a case example
1个月前
已完结
Regorafenib: A Review of Its Use in Previously Treated Patients with Progressive Metastatic Colorectal Cancer
1个月前
已完结
皖公网安备34019202002308
